Should I buy MetLife (MET) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (318 calls tested). It aims for $103 (+7.0 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).
Firm-by-firm track record on MetLife
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 86 % | +25.4 % | 7 | $105 +9% |
| Morgan Stanley | 78 % | +18.4 % | 40 | $111 +15% |
| JP Morgan | 58 % | +12.8 % | 12 | $108 +12% |
| Wells Fargo | 62 % | +12.1 % | 21 | $109 +13% |
| Jefferies | 83 % | +11.7 % | 6 | $103 +7% |
| Piper Sandler | 50 % | +10.4 % | 8 | $90 -6% |
| Keefe, Bruyette & Woods | 75 % | +9.5 % | 12 | $108 +12% |
| Barclays | 61 % | +4.9 % | 18 | $97 +1% |
✅ Reasons to believe
- 83% of analysts rate it a buy (Buy consensus, 12 ratings) — a sign of market conviction.
- Median price target $104, i.e. +8% from the current price ($96).
- The most reliable firm on MET, UBS (86% hit rate, 7 scored calls), targets $105 (call made on July 8, 2026, maturing on July 8, 2027) (+9%) in its most recent call, and $95 (call made on November 6, 2025, maturing on November 6, 2026) (-1%) in the one coming due soonest.
- 7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.6% yield), raised for 13 years — regular income on top of potential upside.
- Reasonable valuation (P/E ~18) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 12 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on MET
Median target $104 (+8%) · 12 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in MetLife now?
We won't decide for you. The facts: 83% of analysts rate it a buy, median target $104 (+8%), and UBS (most reliable on MET, 86%) targets $105. Weigh that against valuation (P/E ~18). This is not personalized advice.
Is it too late to invest in MetLife?
Not according to analysts: the median target ($104) is still +8% above the current price ($96) (most reliable on MET: UBS, 86%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is MetLife still worth investing in?
It depends on the gap between the price ($96) and its estimated value: analysts target $104 on median (+8%), with 83% buys (most reliable on MET: UBS, 86%). Cross-check with their real reliability on MET and the cautions above. Information, not advice.
What's the main risk in buying MET?
The consensus is not unanimous: of 12 ratings, 2 are neutral.
→ Go deeper: the full MetLife profile (consensus, analyst reliability, price target, performance).